Company Overview
Cytosorbents Corporation is engaged in the research, development, and commercialization of medical devices within the healthcare sector, specifically focusing on the medical devices industry. The company utilizes a proprietary adsorbent and porous polymer technology platform to deliver blood purification solutions in the United States, Germany, and internationally. As of the latest data, the entity operates with a market capitalization of $37.24M and reports annual revenue of $37.06M, while the specific employee count is not publicly disclosed in available records. These valuation and revenue figures indicate that Cytosorbents Corporation occupies a small-cap position in the broader healthcare market, suggesting a specialized operational scope that relies heavily on the successful scaling of its flagship blood purification products to drive future expansion.
Financial Health
The company reported a trailing twelve-month revenue of $37.06M, yet generated a net income loss of $-8,198,000, while EBITDA stood at $-12,723,000, revealing a significant cost structure where operating expenses and interest costs substantially erode pre-tax profitability. Although the free cash flow figure is not explicitly detailed in the provided data, the net loss combined with a debt load of $29.11M suggests that the company is currently burning capital rather than generating positive cash flow from operations. The gross margin stands at 71.5%, indicating high efficiency in the cost of goods sold for its medical devices, whereas the operating margin of -43.9% and profit margin of -22.1% demonstrate that overhead costs and R&D expenditures are disproportionately high relative to sales volume. On the liquidity front, the company holds $6.25M in cash against $29.11M in total debt, resulting in a debt-to-equity ratio of 493.16, which characterizes a highly leveraged balance sheet rather than a conservative one. Short-term liquidity appears manageable given a current ratio of 2.12, suggesting the firm possesses sufficient current assets to cover its short-term liabilities. Finally, the return on equity is -96.4% and the return on assets is -19.4%, metrics that indicate management is currently destroying shareholder value and utilizing assets inefficiently in the pursuit of commercializing its technology platform.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as infinity, implying that the market does not currently price in immediate earnings recovery or that future earnings are expected to be negative or zero. The price-to-book ratio is 6.31, which indicates that the market is valuing the company at more than six times its net asset value, suggesting a significant premium over book value likely driven by the intangible value of its proprietary polymer technology. Alternative valuation metrics such as the price-to-sales ratio of 1.00 and the EV/EBITDA of -4.72 provide a different perspective, suggesting that the company is being valued on a sales basis rather than profitability, which is common for pre-profitability biotech or medtech firms. Regarding trading range, the stock has a 52-week high of $1.39 and a 52-week low of $0.56; without a specific current price, the relative standing cannot be calculated as a percentage, but the range establishes the recent volatility floor and ceiling for the security. The beta value is not available in the provided facts, so the specific relationship between the stock's price volatility and the broader market index cannot be quantified based on the current data set.
Growth & Income
Revenue growth year-over-year is recorded at 41.6%, while earnings growth is not available due to the company's current net loss status, implying that revenue expansion is not yet translating into proportional profitability improvements. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources back into research, development, and commercialization efforts rather than returning capital to shareholders. This reinvestment strategy aligns with the high gross margin of 71.5% but is constrained by the significant operating losses and negative EBITDA. Overall, the growth and income profile is defined by aggressive top-line expansion coupled with a complete absence of dividend income, positioning the stock as a pure-play growth vehicle for investors seeking exposure to blood purification technology without current income generation.